{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-075451","form_type":"8-K","ticker":"BCYC","cik":"0001761612","company_name":"BICYCLE THERAPEUTICS PLC","filed_at":"2026-06-18T12:21:16+00:00","discovered_at":"2026-06-18T12:25:00.306446+00:00","generated_at":"2026-06-18T12:25:03.838853+00:00","sec_items":["5.07"],"event_type":"other","sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"confidence":"high","headline":"Bicycle Therapeutics shareholders approve all proposals at 2026 AGM","bullets":["98.64% of shares represented; all 9 proposals passed with large majorities.","Felix Baker re-elected with 46.2M for vs 3.4M against; Hervé Hoppenot re-elected with 49.3M for.","Advisory vote on executive compensation passed: 48.7M for, 0.8M against.","Ratification of PwC as auditor for FY2026 passed: 49.4M for, 0.2M against.","Directors' remuneration policy approved: 48.2M for, 1.3M against."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-075451","json":"https://secwatch.observer/filing/0001104659-26-075451.json","markdown":"https://secwatch.observer/filing/0001104659-26-075451.md","text":"https://secwatch.observer/filing/0001104659-26-075451.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1761612/000110465926075451/0001104659-26-075451-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1761612/000110465926075451/tm2618222d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T12:25:03.838853+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"07241501a375973ac5e74de1b46f20fd27b2d0fc","claim":"BICYCLE THERAPEUTICS PLC shareholders approved To re-elect as a director Felix Baker at the 2026-06-17 meeting.","evidence_excerpt":"Proposal 1 – To re-elect as a director Felix Baker For Against Vote Withheld/Abstain 46,171,302 3,364,113 161,493","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1761612/000110465926075451/0001104659-26-075451-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-17"}],"fact_type":"shareholder_vote"},{"claim_id":"0f57c6150c262b60e66ac6937a43a6baf9845f14","claim":"BICYCLE THERAPEUTICS PLC shareholders approved To approve the directors' remuneration policy at the 2026-06-17 meeting.","evidence_excerpt":"Proposal 9 – To approve the directors’ remuneration policy, which policy is set forth in the Company’s definitive proxy statement, and which will take effect immediately after the end of the AGM For Against Vote Withheld/Abstain 48,238,031 1,293,722 165,155","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1761612/000110465926075451/0001104659-26-075451-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-17"}],"fact_type":"shareholder_vote"},{"claim_id":"1a1b2c804a1096c41562490e09e8a4f4eaab7d45","claim":"BICYCLE THERAPEUTICS PLC shareholders approved To approve, on an advisory basis, the compensation of the Company's named executive officers at the 2026-06-17 meeting.","evidence_excerpt":"Proposal 3 – To approve, on an advisory basis, the compensation of the Company’s named executive officers, as disclosed in the Company’s definitive proxy statement For Against Vote Withheld/Abstain 48,748,743 785,032 163,133","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1761612/000110465926075451/0001104659-26-075451-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-17"}],"fact_type":"shareholder_vote"},{"claim_id":"41b046e9bb4273a2a3868ca42ba71d0814430ac5","claim":"BICYCLE THERAPEUTICS PLC shareholders approved To ratify the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the year ending December 31, 2026 at the 2026-06-17 meeting.","evidence_excerpt":"Proposal 4 – To ratify the appointment of PricewaterhouseCoopers LLP, a limited liability partnership organized under the laws of England, as the Company’s independent registered public accounting firm for the year ending December 31, 2026 For Against Vote Withheld/Abstain 49,445,128 232,627 19,153","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1761612/000110465926075451/0001104659-26-075451-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-17"}],"fact_type":"shareholder_vote"},{"claim_id":"82fe8315905d44ead8670eec96eea62affd0a3d5","claim":"BICYCLE THERAPEUTICS PLC shareholders approved To re-appoint PricewaterhouseCoopers LLP as the Company's U.K. statutory auditors to hold office until the conclusion of the next annual general meeting at the 2026-06-17 meeting.","evidence_excerpt":"Proposal 5 – To re-appoint PricewaterhouseCoopers LLP, a limited liability partnership organized under the laws of England, as the Company’s U.K. statutory auditors, to hold office until the conclusion of the next annual general meeting of shareholders For Against Vote Withheld/Abstain 49,441,337 235,008 20,563","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1761612/000110465926075451/0001104659-26-075451-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-17"}],"fact_type":"shareholder_vote"},{"claim_id":"a793e4d032e43b29477a8474e8bfb53ede7835a5","claim":"BICYCLE THERAPEUTICS PLC shareholders approved To receive and adopt the Company's U.K. statutory annual accounts and reports for the year ended December 31, 2025 at the 2026-06-17 meeting.","evidence_excerpt":"Proposal 7 – To receive and adopt the Company’s U.K. statutory annual accounts and reports for the year ended December 31, 2025. For Against Vote Withheld/Abstain 49,138,590 553,781 4,537","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1761612/000110465926075451/0001104659-26-075451-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-17"}],"fact_type":"shareholder_vote"},{"claim_id":"b2afbfc3ed1ac185f82a40ecf5d026a576e0cdc0","claim":"BICYCLE THERAPEUTICS PLC shareholders approved To approve the directors' remuneration report for the year ended December 31, 2025 (excluding the remuneration policy) at the 2026-06-17 meeting.","evidence_excerpt":"Proposal 8 – To approve the directors’ remuneration report for the year ended December 31, 2025, which report is set forth in the Company’s definitive proxy statement (excluding the directors’ remuneration policy) For Against Vote Withheld/Abstain 48,741,517 792,394 162,997","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1761612/000110465926075451/0001104659-26-075451-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-17"}],"fact_type":"shareholder_vote"},{"claim_id":"d70c1c95d8cb693b197b5e34176c52a9c0f50580","claim":"BICYCLE THERAPEUTICS PLC shareholders approved To authorize the Audit Committee to determine the Company's U.K. statutory auditors' remuneration for the year ending December 31, 2026 at the 2026-06-17 meeting.","evidence_excerpt":"Proposal 6 – To authorize the Audit Committee of the Company’s Board of Directors to determine the Company’s U.K. statutory auditors’ remuneration for the year ending December 31, 2026 For Against Vote Withheld/Abstain 49,493,240 47,269 156,399","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1761612/000110465926075451/0001104659-26-075451-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-17"}],"fact_type":"shareholder_vote"},{"claim_id":"f798bcf54ccd50560d47d36f644ddeedf0524e2b","claim":"BICYCLE THERAPEUTICS PLC shareholders approved To re-elect as a director Hervé Hoppenot at the 2026-06-17 meeting.","evidence_excerpt":"Proposal 2 – To re-elect as a director Hervé Hoppenot For Against Vote Withheld/Abstain 49,284,459 250,669 161,780","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1761612/000110465926075451/0001104659-26-075451-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-17"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}